

Scott R Plotkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5319782/publications.pdf>

Version: 2024-02-01

194
papers

11,087
citations

41627

51
h-index

37326

100
g-index

208
all docs

208
docs citations

208
times ranked

11126
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofibromatoses. Hematology/Oncology Clinics of North America, 2022, 36, 253-267.	0.9	8
2	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 452-460.	3.2	29
3	Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet Journal of Rare Diseases, 2022, 17, 44.	1.2	1
4	Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist, 2022, 27, 518-524.	1.9	6
5	Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery, 2022, 90, 506-514.	0.6	6
6	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	0.6	62
7	Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2413-2420.	0.7	3
8	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977.	1.1	60
9	Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy - Methods and Clinical Development, 2022, , .	1.8	5
10	Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. American Journal of Medical Genetics, Part A, 2022, 188, 2672-2683.	0.7	4
11	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathologica, 2021, 141, 101-116.	3.9	26
12	Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Education and Counseling, 2021, 104, 808-814.	1.0	5
13	DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI. IEEE Journal of Biomedical and Health Informatics, 2021, PP, 1-1.	3.9	1
14	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	15.2	46
15	The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet Journal of Rare Diseases, 2021, 16, 61.	1.2	15
16	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology, 2021, 39, 797-806.	0.8	54
17	Identifying challenges in neurofibromatosis: a modified Delphi procedure. European Journal of Human Genetics, 2021, 29, 1625-1633.	1.4	7
18	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23, 1506-1513.	1.1	290

#	ARTICLE	IF	CITATIONS
19	Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1508-1514.	1.7	3
20	Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591.	1.9	11
21	Validating Techniques for Measurement of Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S32-S41.	1.5	6
22	Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S25-S31.	1.5	8
23	Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S15-S24.	1.5	5
24	Neurofibromatosis Clinical Trials REiNS Collaboration 2020 Recommendations. <i>Neurology</i> , 2021, 97, .	1.5	2
25	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. <i>Neurology</i> , 2021, 97, S99-S110.	1.5	2
26	Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S111-S119.	1.5	6
27	Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement. <i>Neurology</i> , 2021, 97, S4-S14.	1.5	7
28	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. <i>PLoS ONE</i> , 2021, 16, e0252048.	1.1	19
29	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	21
30	Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 1342-1346.	0.3	0
31	mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. <i>Journal of Biological Chemistry</i> , 2021, 296, 100157.	1.6	8
32	Are Some Randomized Clinical Trials Impossible?. <i>Journal of Pediatric Orthopaedics</i> , 2021, 41, e90-e93.	0.6	5
33	INNV-04. A MULTI-INSTITUTIONAL CLINICAL AND MRI REPOSITORY OF NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PERIPHERAL NERVE SHEATH TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi105-vi106.	0.6	1
34	CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi62-vi63.	0.6	0
35	NIMG-08. A MULTI-CENTER RADIOMICS-BASED MODEL TO DIFFERENTIATE BETWEEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi128-vi129.	0.6	0
36	A practical guide to neuro-oncology fellowship. <i>Journal of Neuro-Oncology</i> , 2021, , 1.	1.4	1

#	ARTICLE	IF	CITATIONS
37	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	0.6	0
38	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	3.2	48
39	Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. <i>General Hospital Psychiatry</i> , 2020, 62, 72-78.	1.2	16
40	NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI. <i>Neuro-Oncology</i> , 2020, 22, ii148-ii148.	0.6	0
41	Correlation between NF1 genotype and imaging phenotype on whole-body MRI. <i>Neurology</i> , 2020, 94, e2521-e2531.	1.5	12
42	Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 593-613.	1.5	21
43	Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. <i>Journal of Neuro-Oncology</i> , 2020, 147, 451-457.	1.4	8
44	The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. <i>Oncologist</i> , 2020, 25, e1109-e1116.	1.9	53
45	CTNI-18. FINAL RESULTS OF A PHASE 2 STUDY OF EFFICACY, SAFETY AND INTRATUMORAL PHARMACOKINETICS (PK) OF SELINEXOR MONOTHERAPY IN RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2020, 22, ii46-ii46.	0.6	1
46	Familial Nervous System Tumor Syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1523-1552.	0.4	1
47	BIOM-26. MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2020, 22, ii7-ii7.	0.6	0
48	CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). <i>Neuro-Oncology</i> , 2020, 22, ii43-ii43.	0.6	0
49	EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii69-ii70.	0.6	0
50	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73
51	THER-07. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, ii115-ii115.	0.6	0
52	Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial. <i>Journal of Neuro-Oncology</i> , 2019, 145, 561-569.	1.4	7
53	First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. <i>Journal of Neuro-Oncology</i> , 2019, 143, 505-513.	1.4	14
54	ACTR-09. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi14-vi14.	0.6	0

#	ARTICLE	IF	CITATIONS
55	NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE. <i>Neuro-Oncology</i> , 2019, 21, vi176-vi176.	0.6	0
56	A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. <i>Nature Protocols</i> , 2019, 14, 541-555.	5.5	18
57	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2077-E2084.	3.3	32
58	Pain correlates with germline mutation in schwannomatosis. <i>Medicine (United States)</i> , 2018, 97, e9717.	0.4	20
59	Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2018, 39, 632-638.	0.7	15
60	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018, 102, 69-87.	2.6	144
61	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Academic Radiology</i> , 2018, 25, 144-152.	1.3	17
62	Neurofibromatosis and Schwannomatosis. <i>Seminars in Neurology</i> , 2018, 38, 073-085.	0.5	53
63	Anti-VEGF treatment improves neurological function in tumors of the nervous system. <i>Experimental Neurology</i> , 2018, 299, 326-333.	2.0	14
64	Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. <i>Journal of Neuro-Oncology</i> , 2018, 136, 335-342.	1.4	7
65	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. <i>Scientific Reports</i> , 2018, 8, 17062.	1.6	11
66	ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	0.6	1
67	INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE. <i>Neuro-Oncology</i> , 2018, 20, vi142-vi142.	0.6	2
68	CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi52-vi52.	0.6	0
69	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	0.6	14
70	Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. <i>BMC Health Services Research</i> , 2018, 18, 668.	0.9	19
71	NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i144-i144.	0.6	0
72	NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. <i>Neuro-Oncology</i> , 2018, 20, i142-i142.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Benign Intracranial Tumors. <i>Neurologic Clinics</i> , 2018, 36, 501-516.	0.8	11
74	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. <i>PLoS ONE</i> , 2018, 13, e0197350.	1.1	17
75	Cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S5-S13.	1.5	79
76	Considerations for development of therapies for cutaneous neurofibroma. <i>Neurology</i> , 2018, 91, S21-S30.	1.5	23
77	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1185-1196.	0.6	22
78	Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11008.	0.5	35
79	First report of factors associated with satisfaction in patients with neurofibromatosis. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 671-677.	0.7	9
80	First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. <i>Journal of Neuro-Oncology</i> , 2017, 131, 413-419.	1.4	13
81	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	16
82	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. <i>Npj Precision Oncology</i> , 2017, 1, 33.	2.3	27
83	Health-related Quality of Life of Individuals With Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2016, 37, 574-579.	0.7	18
84	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	2.0	53
85	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. <i>Neurology</i> , 2016, 87, S40-8.	1.5	23
86	Consensus for NF clinical trials. <i>Neurology</i> , 2016, 87, .	1.5	7
87	Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. <i>Neurology</i> , 2016, 87, S13-20.	1.5	15
88	Mind-body therapy via videoconferencing in patients with neurofibromatosis. <i>Neurology</i> , 2016, 87, 806-814.	1.5	82
89	Current whole-body MRI applications in the neurofibromatoses. <i>Neurology</i> , 2016, 87, S31-9.	1.5	65
90	Laryngeal Manifestations of Neurofibromatosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 154, 494-497.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2â€“Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	0.8	92
92	Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. <i>Neuro-Oncology</i> , 2016, 18, 624-638.	0.6	94
93	Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1. <i>Stroke</i> , 2016, 47, 60-65.	1.0	59
94	Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. <i>Journal of Medical Genetics</i> , 2015, 52, 557-562.	1.5	40
95	Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. <i>Journal of Neuro-Oncology</i> , 2015, 122, 219-228.	1.4	47
96	Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. <i>Fertility and Sterility</i> , 2015, 103, 761-768.e1.	0.5	23
97	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , 2015, 84, 280-286.	1.5	92
98	Examining perceived cancer risk among patients with neurofibromatosis type 1. <i>Journal of Neuro-Oncology</i> , 2015, 122, 127-133.	1.4	3
99	Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 108-109.	0.7	6
100	Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14676-14681.	3.3	44
101	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	0.6	207
102	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2044-2044.	0.8	4
103	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 4527-4536.	0.8	85
104	A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. <i>Oncotarget</i> , 2015, 6, 16981-16997.	0.8	46
105	Kinome Screen Reveals SGK1 as a Therapeutic Target for NF2: Inhibition of mTORC1/2 is More Effective than Rapamycin. <i>FASEB Journal</i> , 2015, 29, 889.4.	0.2	0
106	The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. <i>Journal of Neuro-Oncology</i> , 2014, 120, 103-109.	1.4	55
107	Teaching Neuro <i>Images</i> : Brain mass with hilar adenopathy. <i>Neurology</i> , 2014, 82, e161-2.	1.5	2
108	Chemoprevention for neurofibromatosis 2: just over the horizon?. <i>Neuro-Oncology</i> , 2014, 16, 471-472.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 1431-1437.	0.7	41
110	Magnetic Resonance Imaging Observations in Primary Central Nervous System Lymphoma. <i>JAMA Neurology</i> , 2014, 71, 918.	4.5	4
111	Anatomic and Metabolic Evaluation of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis 1 Using Whole-Body MRI and 18F-FDG PET Fusion. <i>Clinical Nuclear Medicine</i> , 2014, 39, e301-e307.	0.7	18
112	Update from the 2013 international neurofibromatosis conference. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 2969-2978.	0.7	17
113	Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1197-1204.	1.1	63
114	Turner syndrome and meningioma: Support for a possible increased risk of neoplasia in Turner syndrome. <i>European Journal of Medical Genetics</i> , 2014, 57, 269-274.	0.7	19
115	Posterior Reversible Encephalopathy Syndrome (PRES) Complicating Newly-Diagnosed Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e111-e113.	0.2	6
116	Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients. <i>Otology and Neurotology</i> , 2014, 35, e50-e56.	0.7	60
117	Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. <i>Journal of Neuro-Oncology</i> , 2013, 114, 257-262.	1.4	81
118	Neurofibromatosis type 1 and pregnancy complications: a population-based study. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 46.e1-46.e8.	0.7	48
119	Plasma S100 β is not a useful biomarker for tumor burden in neurofibromatosis. <i>Clinical Biochemistry</i> , 2013, 46, 698-700.	0.8	5
120	Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 146-153.	1.1	87
121	Conclusions and future directions for the REiNS International Collaboration. <i>Neurology</i> , 2013, 81, S41-4.	1.5	23
122	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 1079-1087.	0.6	205
123	Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1. <i>Journal of Neurosurgery</i> , 2013, 118, 142-148.	0.9	65
124	Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 930-935.	0.6	77
125	Recommendations for imaging tumor response in neurofibromatosis clinical trials. <i>Neurology</i> , 2013, 81, S33-40.	1.5	107
126	Achieving consensus for clinical trials. <i>Neurology</i> , 2013, 81, S1-5.	1.5	59

#	ARTICLE	IF	CITATIONS
127	Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. <i>Neurology</i> , 2013, 81, S25-32.	1.5	36
128	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19059-19064.	3.3	303
129	Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-awareness. <i>Psycho-Oncology</i> , 2013, 22, 2711-2719.	1.0	23
130	Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients. <i>PLoS ONE</i> , 2013, 8, e59941.	1.1	88
131	Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. <i>ISRN Radiology</i> , 2013, 2013, 1-9.	1.2	24
132	Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study. <i>Neuro-Oncology</i> , 2012, 14, 768-776.	0.6	40
133	Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2012, 33, 1046-1052.	0.7	206
134	Facial Reanimation of Patients With Neurofibromatosis Type 2. <i>Operative Neurosurgery</i> , 2012, 70, ons237-ons243.	0.4	9
135	Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. <i>Human Molecular Genetics</i> , 2012, 21, 5239-5245.	1.4	51
136	Chemotherapy. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 471-486.	0.5	6
137	Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients. <i>Oncologist</i> , 2012, 17, 1317-1322.	1.9	171
138	Case 29-2012. <i>New England Journal of Medicine</i> , 2012, 367, 1136-1147.	13.9	4
139	Neurofibromatoses. <i>Advances in Experimental Medicine and Biology</i> , 2012, 724, 266-277.	0.8	27
140	Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. <i>Genetics in Medicine</i> , 2012, 14, 977-982.	1.1	80
141	Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis. <i>PLoS ONE</i> , 2012, 7, e35711.	1.1	126
142	Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. <i>Skeletal Radiology</i> , 2012, 41, 917-923.	1.2	28
143	Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. <i>Neuropathology</i> , 2012, 32, 611-616.	0.7	28
144	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 24-41.	0.7	101

#	ARTICLE	IF	CITATIONS
145	Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2011, 103, 325-332.	1.4	82
146	Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. <i>Journal of Neurosurgery: Spine</i> , 2011, 14, 543-547.	0.9	104
147	Exacerbation of Cerebral Radiation Necrosis by Bevacizumab. <i>Journal of Clinical Oncology</i> , 2011, 29, e159-e162.	0.8	77
148	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape. <i>Cancer Research</i> , 2011, 71, 19-28.	0.4	186
149	Genetic Syndromes. , 2011, , 457-497.		0
150	Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients. <i>Otology and Neurotology</i> , 2010, 31, 1135-1143.	0.7	91
151	Facial Reanimation of Patients with Neurofibromatosis Type 2. <i>Laryngoscope</i> , 2010, 120, S108-S108.	1.1	1
152	Anti"Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors. <i>Cancer Research</i> , 2010, 70, 3483-3493.	0.4	100
153	Use of Video to Facilitate End-of-Life Discussions With Patients With Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 305-310.	0.8	215
154	Phase II Study of Cediranib, an Oral Pan"Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2817-2823.	0.8	489
155	Neurofibromatosis and Schwannomatosis. , 2010, , 181-193.		1
156	NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth. <i>Molecular and Cellular Biology</i> , 2009, 29, 4250-4261.	1.1	264
157	Tumor Burden in Patients with Neurofibromatosis Types 1 and 2 and Schwannomatosis: Determination on Whole-Body MR Images. <i>Radiology</i> , 2009, 250, 665-673.	3.6	102
158	Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2. <i>New England Journal of Medicine</i> , 2009, 361, 358-367.	13.9	446
159	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. <i>Journal of Neuro-Oncology</i> , 2009, 93, 61-77.	1.4	48
160	Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. <i>BMC Medical Genomics</i> , 2009, 2, 42.	0.7	39
161	Identity analysis of schwannomatosis kindreds with recurrent constitutional <i>SMARCB1</i> (INI1) alterations. <i>Clinical Genetics</i> , 2009, 75, 501-502.	1.0	9
162	High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL).. <i>Blood</i> , 2009, 114, 1672-1672.	0.6	3

#	ARTICLE	IF	CITATIONS
163	The Neurofibromatoses. Part 1: NF1. Reviews in Neurological Diseases, 2009, 6, E47-53.	0.3	41
164	The neurofibromatoses. Part 2: NF2 and schwannomatosis. Reviews in Neurological Diseases, 2009, 6, E81-6.	0.3	49
165	Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain. Journal of Neuro-Oncology, 2008, 86, 55-56.	1.4	1
166	Brain metastases. Current Treatment Options in Neurology, 2008, 10, 308-314.	0.7	22
167	Alterations in the <i>SMARCB1</i> (<i>INI1</i>) tumor suppressor gene in familial schwannomatosis. Clinical Genetics, 2008, 74, 358-366.	1.0	136
168	Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiology of Disease, 2008, 29, 278-292.	2.1	42
169	Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology, 2008, 26, 5610-5617.	0.8	448
170	Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nature Clinical Practice Oncology, 2008, 5, 487-491.	4.3	67
171	Patient and Physician Attitudes Regarding Clinical Trials in Neurofibromatosis 1. Journal of Neuroscience Nursing, 2008, 40, 341-345.	0.7	5
172	THREE-DIMENSIONAL VOLUMETRICS FOR TRACKING VESTIBULAR SCHWANNOMA GROWTH IN NEUROFIBROMATOSIS TYPE II. Neurosurgery, 2008, 62, 1314-1320.	0.6	90
173	Case 11-2007. New England Journal of Medicine, 2007, 356, 1561-1570.	13.9	13
174	Value of PET in the Assessment of Patients with Neurofibromatosis Type 1. American Journal of Roentgenology, 2007, 189, 928-935.	1.0	129
175	Clinical Reasoning: A case of multiple intracerebral hemorrhages. Neurology, 2007, 69, E30-E34.	1.5	3
176	Genetic Causes of Brain Tumors: Neurofibromatosis, Tuberous Sclerosis, von Hippel-Lindau, and Other Syndromes. Neurologic Clinics, 2007, 25, 925-946.	0.8	126
177	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 2007, 11, 83-95.	7.7	1,675
178	Precursor B Lymphoblastic Lymphoma Restricted to the Central Nervous System: A Case Report. FASEB Journal, 2007, 21, A391.	0.2	0
179	Update on primary central nervous system lymphoma. Current Opinion in Neurology, 2005, 18, 645-653.	1.8	10
180	Peripheral and cranial nerve sheath tumors. Current Opinion in Neurology, 2005, 18, 604-610.	1.8	96

#	ARTICLE	IF	CITATIONS
181	Facial numbness in a man with inguinal and retroperitoneal masses. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 54-58.	4.3	3
182	Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate. <i>Clinical Cancer Research</i> , 2004, 10, 5643-5646.	3.2	196
183	Neurologic complications of cancer therapy. <i>Neurologic Clinics</i> , 2003, 21, 279-318.	0.8	76
184	Brain Metastases. , 2003, , 1101-1107.		5
185	Primary nervous system lymphoma. <i>Current Treatment Options in Oncology</i> , 2002, 3, 525-535.	1.3	2
186	Advances in the Therapy of Primary Central Nervous System Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 1, 263-275.	2.1	12
187	Primary nervous-system lymphoma. <i>Lancet Oncology</i> , The, 2001, 2, 354-365.	5.1	46
188	Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance. <i>Pharmacology Biochemistry and Behavior</i> , 2001, 68, 379-387.	1.3	11
189	Traumatic Cervical-Spine Disruption. <i>New England Journal of Medicine</i> , 2001, 345, 1134-1135.	13.9	4
190	Differential transport of rat and human interleukin-1 β across the blood-brain barrier and blood-testis barrier in rats. <i>Brain Research</i> , 2000, 881, 57-61.	1.1	34
191	Folk Remedy Use in the Inner City. <i>Southern Medical Journal</i> , 1999, 92, 795-798.	0.3	12
192	Enkephalin, PPE mRNA, and PTS-1 in alcohol withdrawal seizure-prone and -resistant mice. <i>Alcohol</i> , 1998, 15, 25-31.	0.8	20
193	Ethanol alters the concentration of Met-enkephalin in brain by affecting peptide transport system-1 independent of preproenkephalin mRNA. <i>Journal of Neuroscience Research</i> , 1997, 48, 273-280.	1.3	19
194	Permeability of the Blood-Brain Barrier to Soluble Cytokine Receptors. <i>NeuroImmunoModulation</i> , 1995, 2, 161-165.	0.9	95